So You Want to Be a Biopharmaceutical Analyst?
Biopharmaceutical research continues to highlight the growing importance and commercial impact of biologically derived pharmaceuticals. As the biopharma industry expands, analytical scientists with specialized knowledge in biopharmaceutical applications and techniques are increasingly valuable.
The growing impact of biopharmaceuticals is reshaping the analytical science field. Advances in biological research continue to offer significant potential for understanding complex biological processes. Whether you are at the start of your analytical science career, considering transitioning from academia into industry, or experienced in fields like food or environmental analysis and curious about applying your skills in biopharmaceutical research, there are numerous opportunities to explore.
To support you in navigating this exciting field, The Analytical Scientist, Agilent Technologies, Ireland’s National Institute for Bioprocessing Research and Training (NIBRT), and Axolabs have partnered to provide insightful resources into biopharmaceutical research.
We invite you to explore our digital guide for a comprehensive overview of the opportunities and developments within the biopharmaceutical research community.
Chapter VI: Bioprocessing – Where It All Comes Together
Welcome to the sixth and final chapter of “So You Want to Be a Biopharmaceutical Analyst”
Chapter I: “My Journey into Biopharma”
How do people get involved in biopharma – and what keeps them there? Welcome to the first chapter of “So You Want to Be a Biopharmaceutical Analyst.”
Read HereChapter II: The Wild World of mAb Analytics
Peter O’Byrne, Bioprocessing Trainer, NIBRT, explores the wonder – and complexity – of monoclonal antibodies
Read HereChapter III: Protein Cartography
We asked Tadhg Devlin, Bioprocessing Trainer at NIBRT, to provide an overview on the basics of peptide mapping – a crucial quality control step.
Read HereChapter IV: As Easy as ADC?
If you thought a monoclonal antibody was complex, what if we connect it to a potent cytotoxic drug with a special linker molecule?
Read HereChapter V: Oligos Go Mainstream
Axolabs’ Ingo Röhl takes us back to the early days of oligonucleotides, through a pandemic, to the promise of tomorrow
Read Here